69455-12-5

Basic information

• Product Name: 4-(benzyloxy)-3-bromobenzenecarbaldehyde
• Synonyms: 4-(benzyloxy)-3-bromobenzenecarbaldehyde;4-(benzyloxy)-3-bromobenzaldehyde(SALTDATA: FREE);3-bromo-4-phenylmethoxybenzaldehyde
• CAS NO: 69455-12-5
• Molecular Formula: C₁₄H₁₁BrO₂
• Molecular Weight: 291.15
• Mol File: 69455-12-5.mol
• Article Data: 18

Chemical Properties

• Melting Point: 96-99°
• Boiling Point: 406.3°C at 760 mmHg
• Flash Point: 199.5°C
• Appearance: /
• Density: 1.441g/cm³
• Vapor Pressure: 8.22E-07mmHg at 25°C
• Refractive Index: 1.629
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: 4-(benzyloxy)-3-bromobenzenecarbaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(benzyloxy)-3-bromobenzenecarbaldehyde(69455-12-5)
• EPA Substance Registry System: 4-(benzyloxy)-3-bromobenzenecarbaldehyde(69455-12-5)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 69455-12-5(Hazardous Substances Data)

Usage

General Description

4-(benzyloxy)-3-bromobenzenecarbaldehyde is an organic compound with the chemical formula C14H11BrO2. It is a crystalline solid that is commonly used in organic synthesis and as a building block for other chemicals. The compound contains a benzene ring with a bromine atom and a aldehyde functional group attached to it, as well as a benzyloxy group in the para position. It is often used in the pharmaceutical industry as an intermediate in the synthesis of various pharmaceuticals and is also utilized in the production of fragrances and flavorings. The compound has potential applications in the field of medicinal chemistry and organic chemistry due to its versatile reactivity and functional groups present.

InChI:InChI=1/C14H11BrO2/c15-13-8-12(9-16)6-7-14(13)17-10-11-4-2-1-3-5-11/h1-9H,10H2

Upstream product

• 123-08-0 4-hydroxy-benzaldehyde 
• 100-44-7 benzyl chloride 
• 2973-78-6 3-bromo-4-hydroxybenzylaldehyde 
• 100-39-0 benzyl bromide 

Downstream Products

• 4397-53-9 p-benzyloxybenzaldehyde 
• 69455-02-3 1-Benzyloxy-4-(bis-ethylsulfanyl-methyl)-2-bromo-benzene 
• 169209-25-0 TB 17 
• 459430-90-1 [4-(benzyloxy)-3-bromophenyl]methanol 
• 898538-21-1 [4-(benzyloxy)-3-bromophenyl](4-ethoxyphenyl)methanol 
• 1254569-83-9 2,4'-dibenzyloxy-3'-bromodiphenylmethanol 
• 317358-76-2 4-(benzyloxy)-3-bromobenzonitrile 
• 1357091-70-3 [4-benzyloxy-3-(3-carbamoylphenyl)phenyl]-N-cyclohexylcarbamate 
• 1357160-72-5 URB₉₃₇ 
• 1395312-62-5 (Z)-methyl 3-(4-(benzyloxy)-3-bromophenyl)-2-(tert-butyldimethylsilyloxy)acrylate 
• 1395313-28-6 (E)-methyl 3-(4-(benzyloxy)-3-bromophenyl)-2-(tert-butyldimethylsilyloxy)acrylate 

Relevant articles and documents

PLATELET AGGREGATION INHIBITOR, PREPARATION AND USES THEREOF

This disclosure relates to medicines, and more particularly to a platelet aggregation inhibitor, a pharmaceutical composition containing the same and a preparation and application thereof. The platelet aggregation inhibitor provided herein is a compound of formula (I), or a pharmaceutically-acceptable salt, a tautomer or a pharmaceutically-acceptable solvate thereof. This application also provides an application of the compound of formula (I), or a pharmaceutically-acceptable salt, a tautomer, a pharmaceutically-acceptable solvate or a pharmaceutical composition thereof in the treatment of thrombus.

Design, synthesis and biological evaluation of 1-hydroxy-2-phenyl-4-pyridyl-1H-imidazole derivatives as xanthine oxidase inhibitors

In our previous study, we reported a series of 1-hydroxy-2-phenyl-1H-imidazole-5-carboxylic acid derivatives that presented excellent in vitro xanthine oxidase inhibitory potency. As a continuation study, a series of 1-hydroxy-2-phenyl-1H-imidazole derivatives containing a pyridine moiety (4a-g and 5a-g) at the 4-position was designed and synthesized. Evaluation of in vitro xanthine oxidase inhibition demonstrated that the 4a-g series was more potent than the 5a-g series. Compound 4f was the most promising derivative in the series with an IC50 value of 0.64 μM. A Lineweaver-Burk plot revealed that compound 4f acted as a mixed-type xanthine oxidase inhibitor. An iso-pentyloxy group at the 4′-position improved the inhibitory potency. More interestingly, structure-activity relationship analysis indicated that the pyridine para-N atom played a crucial role in the inhibition. Molecular modeling provided a reasonable explanation for the structure-activity relationships observed in this study. In addition, a three dimensional quantitative structure-activity relationships model which possessed reasonable statistics (q2 = 0.885 and r2 = 0.993) was conducted to further understand the structural basis of these compounds as xanthine oxidase inhibitors. These compounds, especially compound 4f, have good potential for further investigations.

PERIPHERALLY RESTRICTED FAAH INHIBITORS

Peripherally restricted inhibitors of fatty acid amide hydrolase (FAAH) are provided. The compounds can suppress FAAH activity and increases anandamide levels outside the central nervous system (CNS). Despite their relative inability to access brain and spinal cord, the compounds attenuate behavioral responses indicative of persistent pain in rodent models of inflammation and peripheral nerve injury, and suppresses noxious stimulus-evoked neuronal activation in spinal cord regions implicated in nociceptive processing. CBi receptor blockade prevents these effects. Accordingly, the invention also provides methods, and pharmaceutical compositions for treating conditions in which the inhibition of peripheral FAAH would be of benefit. The compounds of the invention are according to the formula (I): in which R1 is a polar group. In some embodiments, R1 is selected from the group consisting of hydroxy and the physiologically hydro lysable esters thereof. R2 and R3 are independently selected from the group consisting of hydrogen and substituted or unsubstituted hydrocarbyl; each R4 is independently selected from the group consisting of halogen and substituted or unsubstituted hydrocarbyl and n is an integer from 0 to 4; each R5 is independently selected from the group consisting of halo and substituted or unsubstituted hydrocarbyl and m is an integer from 0 to 3; and R6 is substituted or unsubstituted cyclohexyl; and the pharmaceutically acceptable salts thereof.